Nathan Leader

Clinical Assistant Professor @UCalgary + @LibinInstitute. Echo / Prevention / Sports

[EJHF Editor-in-Chief @EJHFEiC]

Time-dependent outcomes in myocarditis and inflammatory #cardiomyopathy patients treated with the IL-1 receptor antagonist #Anakinra

https://t.co/YTp4jMHVVK

#EJHF @HanCardiomd @AmrAbdin10 @GiuseppeGalati_

[NEJM Clinician @NEJMClinician]

A recent review in @NEJM discusses sudden cardiac arrest management in athletes.

Read the Key Points and a comment from Deputy Editor Ann Cheung, MD, MBA, MS: https://t.co/kJeoI9QOcj

#cardiology

[AJPC @AJPCardio]

New advances in risk assessment and management are shaping updates across international cholesterol guidelines. This forecast highlights shifts in interpretation, thresholds, and treatment strategies to better prevent ASCVD worldwide.
🔗 https://t.co/3g50mJAcBB

#Cholesterol

[Edgardo Alania @Ed_Alania]

🔴Myocarditis & look-alikes: when the diagnosis matters @Heart_BMJ #Cardiology #CardioEd #Myocarditis

[Henry Han @HanCardiomd]

Standardization of Baseline and Provocative Invasive Hemodynamic Protocols for the Evaluation of #HeartFailure and Pulmonary Hypertension: A Scientific Statement From the @AHAScience

https://t.co/LI5dYH3rFf
@CircHF #HFpEF

[European Society of Cardiology Journals @ESC_Journals]

Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease? Read this State-of-the-Art review in #EHJ 👉 https://t.co/izTvcZQG42

@RoccoMontone @ehj_ed

[C. Michael Gibson MD @CMichaelGibson]

OCEAN trial: For AF patients with ≥1 risk factor post-catheter ablation, low-dose rivaroxaban showed similar rates of stroke/systemic embolism and major bleeding at 3 years compared to aspirin. #AHA25 View the slides here: https://t.co/FMhUbroiyp

[Adam Cifu @adamcifu]

What a strange conclusion for this article. I'd edit it to:
Among older nursing home residents with frailty who were receiving treatment with antihypertensive agents and had a systolic blood pressure below 130 mm Hg, an antihypertensive treatment step-down strategy was safe.
H/T @AndrewFoy82

Reduction of Antihypertensive Treatment in Nursing Home Residents | New England Journal of Medicine https://t.co/OZpHhhD5jz

[Circulation @CircAHA]

Early Surgery for Asymptomatic Severe MR @SahminL https://t.co/iENQyQUvSA

[J. Sawalla Guseh, M.D. @JSawallaGusehMD]

You don't need to be a competitive athlete to have an athlete's heart. Regular exercise—especially over 5 hours weekly—reshapes the heart, boosting health and performance.

https://t.co/BSiKjnai8D

[EJHF Editor-in-Chief @EJHFEiC]

🗞️ Impact of genotype–phenotype associations on prognosis in #DilatedCardiomyopathy

@ESC_Journals @GiuseppeGalati_

@AmrAbdin10 @HanCardiomd

https://t.co/ANOipYFXI4

[SportsCardiology @Sports_CardioNL]

Pre-participation screening in competitive athletes in Italy: an analysis of real-world practice from a large database
https://t.co/gD7O859la0
#preparticipationscreening #ECG #Sportscardiology #athlete

[ERM @Owner_X429]

Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: https://t.co/oVJpDstmg3

[European Society of Cardiology @escardio]

#ESCCongressVisuals from Hot Line 3👇

Given the progress made in the management of acute myocardial infarctions, it is important to understand whether beta blockers still have a role in those with mildly reduced EF. Will the REBOOT trial demonstrate a reduction in the rates of death, reinfarction or hospital admission for heart failure? 👇

The large combined Danish (DANBLOCK) and Norwegian (BETAMI) randomised beta-blocker trials provide evidence on the use of beta blockers post-MI in patients with preserved EF. Will there be a reduction in a composite of recurrent MI, all cause mortality, malignant VT, cardiac arrest and HF? 👇

REBOOT/BETAMI/DANBLOCK/CAPITAL-RCT: This large meta-analysis provides the largest dataset to date to determine the efficacy of beta blockers in improving outcomes post-MI in those with mildly reduced EF. 👇

Will noninvasive assessment permit identification of high risk post-MI patients with preserved LV function? How will ICD use post-MI change after the results are shared? Will this trial impact guidelines? 👇

#ESCCongress

[European Society of Cardiology @escardio]

#ESCCongressVisuals from Hot Line 5👇

DANCANVAS 2 attempts to reduce social inequality in cardiovascular health by performing an interventional screening trial on how best to decrease cardiovascular disease amongst individuals of low social status. 👇

PREVENT-MINS is a multicentre, superiority randomized controlled trial of ivabradine versus placebo. The primary objective is to determine the impact of ivabradine on the risk of MI in patients 30 days after noncardiac surgery 👇

The ABC-AF study evaluates whether a personalized treatment recommendation strategy-guided by the biomarkers improves outcomes in AF. How generalizable is this study? 👇

Patients with acute VTE in the setting of transient provoking factors are treated with short-term anticoagulation. However, the risk of recurrence may increase if there are enduring risk factors. Will patients receiving extended treatment of apixaban reduce recurrence rates? HI-PRO is a single-center, double-blind randomized trial that answers this question. 👇

#ESCCongress #ESCCongressVisuals

[Raviele Antonio @drraviele]

WITHDRAW-AF RCT
📌 In👫w/ presumed AF-induced #cardiomyopathy & normalized #LVEF after SR restoration
👉 withdrawal of #HF therapy is not assoc w/ LVEF ⬇️ again in 90% of👫in the following 6-m
#EPeeps #afib #HeartFailure #CardioTwitter #MedTwitter @DrMarthaGulati @JagSinghMD

[JACC Journals @JACCJournals]

Lipid management remains key in preventing #ASCVD. While statins are foundational, nonstatin therapies are expanding fast. This expert panel reviews current international recommendations regarding lipid management. https://t.co/LaJdiTsbeO

#cvLipids #JACCAdvances

[National Lipid Association @nationallipid]

📉Lower LDL-C for longer is better.

The NLA’s new guidance simplifies LDL-C management for adults — helping clinicians & patients improve evidence-based measurement and treatment of LDL-C.

Read the guidelines & recommendations: https://t.co/ofc5QVVPXO. @LipidCNS @CBallantyneMD

[Raviele Antonio @drraviele]

📌 Figure illustrating
👉 Causes of AF in the young 👫
#afib #EPeeps #CardioTwitter #MedTwitter #SportsCardiology #Review #ECG @shivkumarmd @DrJasonAndrade @DhirajGuptaBHRS @SSharmacardio @tomdepotter @ecgrhythms @mmamas1973 @SeguraCardio @gonzaeperez @ErinMichos @Hragy @ftrae

[Broderick Cardiomyopathy Program @BroderickHeart]

A Gift from the Heart.

Our community thanks the Broderick family for their leadership and philanthropy.

@LibinInstitute @HotchkissBrain @UCalgaryMed